Flag of the European Union EU Clinical Trials Register Help

Clinical trials for FISH

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    691 result(s) found for: FISH. Displaying page 1 of 35.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-005173-32 Sponsor Protocol Number: K-489DK Start Date*: 2013-07-09
    Sponsor Name:FAST-consortium
    Full Title: FAST-Fish - Food Allergy Specific Treatment for fish allergy
    Medical condition: Fish Allergy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000276-10 Sponsor Protocol Number: FAST2015 Start Date*: 2015-07-02
    Sponsor Name:FAST Consortium under EU 7. FWP
    Full Title: FAST – Food Allergy Specific ImmunoTherapy A multinational phase IIb study to investigate the efficacy and safety of subcutaneous immunotherapy with a modified fish- parvalbumin given in single ri...
    Medical condition: Food allergy to fish
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IS (Completed) DK (Completed) GR (Ongoing) NL (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004404-21 Sponsor Protocol Number: SLE-Omega Start Date*: 2004-12-10
    Sponsor Name:GreenPark Healthcare Trust [...]
    1. GreenPark Healthcare Trust
    2. Queens University Belfast
    Full Title: Omega-3-Polyunsaturated Fatty Acids and Atherosclerosis in Systemic Lupus Erythematosus: Cellular Mechanisms and Functional Consequences
    Medical condition: Systemic Lupus Erythematosus
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-005456-33 Sponsor Protocol Number: Start Date*: 2012-01-26
    Sponsor Name:Med. Univ. Wien, Universitätsklinik für Kinder- und Jugendheilkunde
    Full Title: PREVENTING CHOLESTASIS IN PREMATURE INFANTS USING SMOFLIPID
    Medical condition: • To compare a mixed parenteral lipid emulsion containing fish oil (SMOFlipid®) with a soybean oil based lipid emulsion (Intralipid®) for its effect on the occurrence of parenteral nutrition associ...
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002715-10 Sponsor Protocol Number: FAR-NP-2018-01 Start Date*: 2019-02-08
    Sponsor Name:Elisabet Leiva Badosa. Phamacy Department. Hospital Universitari de Bellvitge
    Full Title: RANDOMIZED, DOUBLE-BLIND, PILOT CLINICAL TRIAL TO COMPARE THE EFFICACY AND SAFETY OF FISH OIL-BASED INTRAVENOUS LIPID EMULSIONS IN HOSPITALIZED ADULT PATIENTS TREATED WITH TOTAL PARENTERAL NUTRITIO...
    Medical condition: Hypertriglyceridemia is a frequent metabolic complication associated with the administration of lipidic emulsion in total parenteral nutrition.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003950-24 Sponsor Protocol Number: EOX1.4 Start Date*: 2012-02-14
    Sponsor Name:University Hospitals of Leicester NHS Trust
    Full Title: PHASE II TRIAL OF PALLIATIVE EPIRUBICIN, OXALIPLATIN & CAPECITABINE (EOX) CHEMOTHERAPY COMBINED WITH OMEGA-3 FISH OIL INFUSION (OMEGAVEN) IN PATIENTS WITH OESOPHAGO-GASTRIC CARCINOMA
    Medical condition: Unresectable oesophageal and/or gastric cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005934-11 Sponsor Protocol Number: RNLICCCWF1 Start Date*: 2006-07-11
    Sponsor Name:Cornwall College Camborne [...]
    1. Cornwall College Camborne
    2. Royal National Lifeboat Institution
    Full Title: Investigating the possible Therapeutic Effects of the Homoeopathic Remedy Apis Mellifica on Weaver Fish Stings using a Double Blind Randomised Control Trial.
    Medical condition: Our medical condition is classified as T63.5 according to the World Health organisation (WHO) International classification of disease. this will be an immunological response to the venom contained ...
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003902-14 Sponsor Protocol Number: 16-118 Start Date*: 2017-07-06
    Sponsor Name:RWTH Aachen University, represented by the Clinical Trial Center (CTC-A)
    Full Title: Intravenous Fish Oil based Lipid Emulsion as Pharmaconutrient Strategy in High-Risk Cardiac Surgery Patients: a Phase II Dosing Study
    Medical condition: Given the recently meta-analyzed data from previous RCTs about fish oil , we hypothesize that the provision of intravenous (i.v.) FO (0.20 g/kg and 0.50 g/kg) to cardiac surgery patients may reduc...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004350-28 Sponsor Protocol Number: VEG20007 Start Date*: 2006-08-22
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Phase II, Open-Label, Randomized, Multicenter Trial of GW786034 (Pazopanib) in Combination with Lapatinib (GW572016) Compared to Lapatinib Alone as First Line Therapy in Subjects with Advanced or...
    Medical condition: Advanced or metastatic breast cancer with ErbB2 FISH postive tumours
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2005-002380-90 Sponsor Protocol Number: IVN3DIALYSE Start Date*: 2005-09-26
    Sponsor Name:Nyremedicinsk afdeling, Aalborg Sygehus
    Full Title: Effekten af intravenøs infusion af n-3 polyumættede fedtsyrer på risikomarkører for pludselig hjertedød hos hæmodialysepatienter
    Medical condition: Chronic renal failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018660-16 Sponsor Protocol Number: SAP version1 01/01/2010 Start Date*: 2010-04-22
    Sponsor Name:University Hospitals of leicester NHS Trust
    Full Title: Randomised controlled trial on the effects of parenteral fish oil emulsion in patients with severe acute pancreatitis
    Medical condition: Acute Pancreatitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-002018-23 Sponsor Protocol Number: ONC-2008-001 Start Date*: 2008-10-21
    Sponsor Name:FONDAZIONE HUMANITAS PER LA RICERCA
    Full Title: MULTICENTRIC RANDOMIZED PHASE III STUDY COMPARING GEFITINIB VERSUS PLATINUM-BASED CHEMOTHERAPY IN EGFR FISH POSITIVE NSCLC PATIENTS (RANGE)
    Medical condition: Patients with locally advanced or metastatic NSCLC, EGFR FISH positive, candidate for a first-line platinum-based chemotherapy will be considered eligible for the trial.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025065 Lung carcinoma cell type unspecified recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-001197-24 Sponsor Protocol Number: D791AC00011 Start Date*: 2006-09-18
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Double-blind, Randomised, Parallel Group, Multi-centre Study Comparing gefitinib 250 mg (IRESSA™) with erlotinib 150 mg (Tarceva®) in Previously Treated Patients with Locally Advanced o...
    Medical condition: Non-small Cell Lung Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) DE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-000642-37 Sponsor Protocol Number: AZD4547-2011 Start Date*: 2011-11-08
    Sponsor Name:Greater Glasgow Health Board [...]
    1. Greater Glasgow Health Board
    2. University of Glasgow
    Full Title: A Phase I/IIa trial of AZD4547 in combination with Cisplatin and Capecitabine (CX)
    Medical condition: Stage 1 - Patients with advanced solid tumours. Stage 2 - Histologically proven adenocarcinoma or undifferentiated carcinoma of the oesophagus, gastro-oesophageal junction, or stomach.
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030139 Oesophageal adenocarcinoma NOS LLT
    16.0 10022891 - Investigations 10060139 Antineutrophil cytoplasmic antibody decreased PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001150 Adenocarcinoma gastric PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-011580-36 Sponsor Protocol Number: 40071 Start Date*: 2011-04-26
    Sponsor Name:EORTC - European Organisation for Research and Treatment of Cancer
    Full Title: Effectiveness of first line treatment with lapatinib and ECF/X in histologically proven adenocarcinoma of the stomach or the esophagogastric junction (metastatic or not amenable to curative surge...
    Medical condition: adenocarcinoma of the stomach or the esophagogastric junction (metastatic or not amenable to curative surgery)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063916 Metastatic gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) DE (Completed) HU (Prematurely Ended) PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005437-53 Sponsor Protocol Number: ITCC053 Start Date*: 2016-11-03
    Sponsor Name:Erasmus Medical Center
    Full Title: A phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies Study ITCC 053
    Medical condition: Malignancies carrying a genetic alteration of ALK, MET or ROS1
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned) IE (Completed) ES (Ongoing) DK (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-007803-10 Sponsor Protocol Number: 3144A2-3005 Start Date*: 2009-08-26
    Sponsor Name:Puma Biotechnology, Inc
    Full Title: A Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer
    Medical condition: ErbB2 Positive Locally Recurrent or Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) DE (Completed) IT (Completed) GB (Completed) ES (Completed) BE (Completed) LV (Completed) PT (Completed) LT (Completed) FR (Completed) GR (Completed) DK (Completed) MT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-002155-17 Sponsor Protocol Number: LAP105594 Start Date*: 2008-04-18
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A phase II open label, multicenter study to evaluate the efficacy and safety of daily dose of Lapatinib in advanced breast cancer patients with HER-2 non-amplified primary tumours and HER-2 positiv...
    Medical condition: Advanced breast cancer patients with HER-2 non-amplified primary tumours and HER-2 positive circulating tumour cells or EGFR positive circulating tumour cells
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057654 Breast cancer female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001264-37 Sponsor Protocol Number: 1200.40 Start Date*: 2008-11-20
    Sponsor Name:BOEHRINGER ING.
    Full Title: A Phase II single-arm trial of BIBW 2992(Tovok) in EGFR FISH positive non-small cell lung cancer patients
    Medical condition: Patients affected by NSCLC EGFR FISH positive.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061873 Non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003633-33 Sponsor Protocol Number: MAXEPA01 Start Date*: 2011-09-29
    Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust
    Full Title: The effect of purified fish oils on glucose regulation in Congenital Hyperinsulinism of Infancy (CHI)
    Medical condition: Congenital hyperinsulinism
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10062329 Congenital endocrine anomaly PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 23:13:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA